UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “Organicell,” “we,” “us” and “our” refer to Organicell Regenerative Medicine, Inc. and its subsidiaries.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On December 21, 2022, John Chiste resigned as a member of the Company’s board of directors.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 23, 2022 | ORGANICELL REGENERATIVE MEDICINE, INC. | |
By: | /s/ Ian Bothwell | |
Ian Bothwell Chief Financial Officer |
2
Cover |
Dec. 21, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 21, 2022 |
Entity File Number | 000-55008 |
Entity Registrant Name | ORGANICELL REGENERATIVE MEDICINE, INC. |
Entity Central Index Key | 0001557376 |
Entity Tax Identification Number | 47-4180540 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 3321 College Avenue |
Entity Address, Address Line Two | Suite 246 |
Entity Address, City or Town | Davie |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33314 |
City Area Code | (888) |
Local Phone Number | 963-7881 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^
M0"X99K>]9!:G
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